LAWRENCEVILLE, N.J.—Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in recurrent chest wall (RCW) breast cancer. The trial is designed to enroll up to 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 17 patients enrolled and treated, 13 were eligible for evaluation of efficacy. Based on data available to date, every patient experienced a clinical benefit of their highly refractory disease within the ThermoDox treatment field, with a local response rate of 69 percent observed in the 13 evaluable patients, including five complete responses (CR), four partial responses (PR) and four patients with stable disease (SD). The company expects to complete enrollment in the study in the third quarter of 2015.
Celsion’s ThermoDox demonstrates impressive clinical response rates in highly refractory form of breast cancer
Planned European trial will evaluate ThermoDox plus hyperthermia and radiation in earlier stage breast cancer patients and is designed to support a registration filing in Europe
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
About the Author
This person does not yet have a bio.View Full Profile
Here are some related topics that may interest you:
LAWRENCEVILLE, N.J.—Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in recurrent chest wall (RCW) breast cancer. The trial is designed to enroll up to 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 17 patients enrolled and treated, 13 were eligible for evaluation of efficacy. Based on data available to date, every patient experienced a clinical benefit of their highly refractory disease within the ThermoDox treatment field, with a local response rate of 69 percent observed in the 13 evaluable patients, including five complete responses (CR), four partial responses (PR) and four patients with stable disease (SD). The company expects to complete enrollment in the study in the third quarter of 2015.
"We have observed durable local responses in two-thirds of the patients treated using ThermoDox in three clinical trials to-date, which is significant considering the fact that these patients present with highly resistant chest wall tumors that had progressed on multiple previous therapies, including chemotherapy, radiation and hormone therapy," noted Dr. Nicholas Borys, Celsion's senior vice president and chief medical officer. "We are aggressively pursuing opportunities to expand this program into Europe through the EURO-DIGNITY trial in which we expect to treat our first patient very soon."
These data are consistent with previously published Phase 1 data for ThermoDox plus hyperthermia in RCW breast cancer. The two similarly designed Phase 1 studies enrolled patients with highly resistant tumors found on the chest wall and who had progressed on previous therapies. Of the 29 patients treated in the two trials, 23 were eligible for evaluation of efficacy. A local response rate of 61 percent was reported in 14 of the 23 evaluable patients, with five complete responses and nine partial responses. A Clinical Response Rate (CR+PR+SD) was observed in 87 percent of the evaluable patients.
"These extremely impressive data position us to successfully pursue and take advantage of promising opportunities to accelerate the development and commercialization of ThermoDox in RCW breast cancer patients as we turn our attention to Europe and the initiation of EURO-DIGNITY, a multi-center study designed to evaluate ThermoDox's potential to locally control chest wall lesions in earlier stage patients," stated Michael H. Tardugno, Celsion's chairman, president and CEO. "Together, through our partnership with myTomorrows and our Early Access Program, our goal is faster commercialization and near-term revenue benefitting patients who are in dire need of more rapid access to new and better options for the treatment of this aggressive form of breast cancer."
San Francisco-based myTomorrows “facilitates early access programs for innovative medical treatments through an independent ‘Honest Broker’ approach,” its website states. “We collaborate with drug developers that have promising new treatments in development and make those treatments available. The empowered physician and patient in today’s connected environment can now gain access to clinical stage compounds through individual Named Patient Programs and cohort-based Compassionate Use Programs.”
The EURO-DIGNITY trial will evaluate ThermoDox plus hyperthermia and radiation in earlier stage breast cancer patients and is designed to support a registration filing in Europe. This study will be conducted in five countries with the support of key European investigators and with assistance from MedLogics Corporation, a hyperthermia device company based in Italy. In addition, Celsion has a license and distribution agreement with myTomorrows to implement an Early Access Program (EAP) for ThermoDox in all countries of the European Union plus Switzerland for the treatment of patients with RCW breast cancer. The company expects to have ThermoDox available in mid-2015 for sale at commercial prices to physicians who are treating patients with limited therapeutic options. The EAP provides physicians with access to products in later stage development that demonstrate evidence of clinical benefit with an acceptable safety profile and a quality manufacturing process in place.
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company's lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase 3 development for the treatment of primary liver cancer. The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™, TheraSilence™ and RAST™.
